Summit Therapeutics Inc.
SMMT · XNASCIK 1599298fmd_04WY1MPYZCVZW8EMVJ0B3V0Y65Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Feb 01, 2015 to Sep 30, 2026, 43 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 16 | 57 | 1 | 2 | 1 | 0 | 0 | – |
| Research and development | 38 | 52 | 53 | 85 | 52 | 59 | 151 | 538 |
| Total operating expenses | 53 | 74 | 73 | 109 | 87 | 610 | 226 | 1,094 |
| Operating income | (28) | 5 | (53) | (86) | (72) | (610) | (226) | – |
| Interest expense | 2 | 1 | 0 | 0 | 4 | 16 | 9 | 0 |
| Interest and investment income | – | 0 | 0 | 0 | 2 | – | – | – |
| Other non-operating income (expense) | – | 4 | 0 | (2) | (2) | 11 | 13 | 15 |
| Income before taxes | (26) | 9 | (53) | (89) | (79) | (615) | (221) | (1,080) |
| Income tax expense | 0 | (2) | (0) | 0 | – | 0 | 0 | 0 |
| Net income from continuing operations | (26) | 11 | (53) | (89) | – | (615) | (221) | (1,080) |
| Net income | (26) | 11 | (53) | (89) | (79) | (615) | (221) | (1,080) |